Correlation between vitiligo occurrence and clinical benefit in advanced melanoma patients treated with nivolumab: A multi‐institutional retrospective studyYasuhiro Nakamura, Akifumi Yamamoto, Manabu Fujimoto et al.|The Journal of Dermatology|2016Cited by 223
Serum level of interleukin-6 is increased in nivolumab-associated psoriasiform dermatitis and tumor necrosis factor-α is a biomarker of nivolumab recativityRyota Tanaka, Manabu Fujimoto, Naoko Okiyama et al.|Journal of Dermatological Science|2016Cited by 132
Correlation between blood cell count and outcome of melanoma patients treated with anti-PD-1 antibodiesYoshiyuki Nakamura, Yasuhiro Fujisawa, Ryota Tanaka et al.|Japanese Journal of Clinical Oncology|2018Cited by 116
Nivolumab-induced chronic inflammatory demyelinating polyradiculoneuropathy mimicking rapid-onset Guillain–Barré syndrome: a case reportRyota Tanaka, Manabu Fujimoto, Hiroshi Maruyama et al.|Japanese Journal of Clinical Oncology|2016Cited by 82
Anti-nuclear matrix protein 2 antibody-positive inflammatory myopathies represent extensive myositis without dermatomyositis-specific rashYuki Ichimura, Naoko Okiyama, Risa Konishi et al.|Lara D. Veeken|2021Cited by 61